Study Evaluating Effexor XR in Elderly Patients With Major Depression.
Phase III Study of Effexor XR for the Treatment of Elderly Patients With Depression
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Listed as NCT00225485, this PHASE3 trial focuses on Depression and remains completed. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 6 times since 2003, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Wyeth is now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adachi-ku, Japan , Chiyoda-ku, Japan , Fuchū, Japan , Hanamaki, Japan , Higashimurayama, Japan , Hiroshima, Japan , Ichikawa, Japan , Kasuga, Japan , Kawasaki, Japan , Kitakyushu, Japan and 15 more locations